Company intelligence / Profile preview

Mucpharm

Sydney, New South Wales, Australiamucpharm.com ↗

Ownership: Private
Development stage: Phase 2

Overview

BromAc® is being explored in phase 2 studies for advanced cancers. The drug removes mucin from cancer cells and sensitizes them to chemotherapy agents. Clinical trials are also investigating BromAc® for respiratory conditions.

Therapeutic areas: OncologyPulmonology
Modalities: Small molecule drugEnzyme
Industry: Biotech

Drug pipeline

1 asset

BromAc

Partnerships

Global collaborative partnerships in Australia, the United States, Brazil, and Europe

Beyond the preview

Go deeper on Mucpharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mucpharm.

Explore the full profile